Human Epidermal Growth Factor Receptor predicts long term outcomes in Ductal Carcinoma In Situ

cancer

New results from researchers at Queen Mary University of London confirm the role of Human Epidermal Growth Factor Receptor (HER2) in predicting long-term outcomes for Ductal Carcinoma In Situ (DCIS), a pre-invasive stage of breast cancer.

The paper published in the journal Clinical Cancer Research also shows that tumours expressing HER2 derive greater benefit from adjuvant radiotherapy, and therefore that HER2 testing will help in personalised treatment selection.

This study shows that HER2 overexpression is associated with significantly increased, almost 3-fold higher risk of in situ recurrence. HER2, a protein expressed in some breast cancer cells, is routinely tested in invasive breast cancer, but its role in DCIS was previously unclear and therefore although the test is widely available in most pathology labs, HER2 is currently not routinely tested in DCIS.

Source: Read Full Article

Related posts:
  1. Hospital staff find themselves on the front lines of war on human trafficking
  2. Low health literacy may be a risk factor for postoperative infection
  3. Loneliness a Risk Factor for Type 2 Diabetes Mellitus
  4. Novel educational program puts a human face on biomedical research
  5. Cat diseases have $6 billion impact on human health in Australia